We Deliver a Thorough Understanding of the Genetic Drivers of Disease
“Pipeline drug targets with human genetic evidence of disease association are twice as likely to lead to approval.”
(King et al. 2019)
Pharma companies need comprehensive genomic informationto drive successful precision medicine programs, but decisions are often made using only a fraction of the data available…about 10%
GENOMENON DELIVERS100% OF THE DATA
5X More Variants in Weeks
Genomenon identified all of the genomic drivers in TARDBP associated with ALS in just two weeks…a yield of 435% more than the number of disease-causing variants found in ClinVar
Comprehensive
Don’t miss anything – get insight into every genomic biomarker published in the medical literature
Evidence-Based
Every scientific assertion is supported by empirical evidence from the medical literature
Genomenon’s comprehensive and organized collection of genomic evidence significantly accelerated our work in several key steps along our development process.
Genomenon’s methodology improved the efficiency and completeness of our literature review process.